Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3926 results
iCardiac Technologies IQ-CSRC study shows potential for faster drug development
The Food and Drug Administration hosted the Cardiac Safety Research Consortium (CSRC) meeting to release the results of the IQ-CSRC Study demonstrating the ability to conduct robust cardiac safety characterization several years earlier in clinical development.
Drug Research > Drug Discovery & Development > News
BioLineRx, Novartis to develop and commercialize Israeli-sourced drug candidates
By PBR Staff Writer
Clinical-stage biopharmaceutical company BioLineRx and Novartis Pharma have reached a multi-year strategic collaboration agreement to support the development and commercialization of Israeli-sourced drug candidates.
Drug Research > Drug Discovery & Development > News
Novogen announces breakthrough discovery melanoma treatment
Novogen, Australian/US biotechnology company, announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.
Drug Research > Drug Discovery & Development > News
ChemoCentryx reports positive results from Phase II diabetic nephropathy trial of CCX140
ChemoCentryx, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced positive top-line 52-week data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2.
Drug Research > Drug Discovery & Development > News
Lakewood-Amedex seeks FDA approval for Phase I/IIa trial of Nu-3 for diabetic foot infections
By PBR Staff Writer
US-based biopharmaceutical firm Lakewood-Amedex has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to conduct a Phase I/IIa trial of Nu-3 as a topical antimicrobial treatment for diabetic foot infections.
Drug Research > Drug Discovery & Development > News
Sunovion reports positive results from first placebo-controlled trial of dasotraline in ADHD patients
Sunovion Pharmaceuticals (Sunovion) announced positive results from the first placebo-controlled clinical study of the company’s investigational drug dasotraline for the treatment of adult patients with attention deficit hyperactivity disorder (ADHD).
Drug Research > Drug Discovery & Development > News
Janssen, USAID to expand access to anti-multidrug-resistant tuberculosis compound
By PBR Staff Writer
Johnson & Johnson's affiliate Janssen Therapeutics has signed a Memorandum of Understanding (MOU) with the US Agency for International Development (USAID) to fight against the antibiotic-resistant bacteria threat.
Drug Research > Drug Discovery & Development > News
Bayer and DNDi to develop an innovative oral treatment for human river blindness
Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis).
Drug Research > Drug Discovery & Development > News
FDA accepts Boston's IND to begin clinical trial of BTI-320 to treat type 2 diabetes and weight loss
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted Boston Therapeutics' investigational new drug (IND) application to start a clinical trial of BTI-320 to treat type 2 diabetes and weight management.
Drug Research > Drug Discovery & Development > News
Spark Therapeutics, Pfizer to develop new treatment paradigm for hemophilia B
By PBR Staff Writer
US-based Spark Therapeutics has entered into a global collaboration with Pfizer to develop and commercialize SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B.
Drug Research > Drug Discovery & Development > News
Amgen initiates Phase I trial of melanoma drug combination
By PBR Staff Writer
US-based Amgen has commenced a Phase I trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, for the treatment of patients with regionally or distantly metastatic melanoma.
Drug Research > Drug Discovery & Development > News
Novo Nordisk reports positive results from phase III trial of NovoEight in haemophilia A people
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment.
Drug Research > Drug Discovery & Development > News
AbbVie releases results from phase II study of venetoclax in acute myelogenous Leukemia
AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML).
Drug Research > Drug Discovery & Development > News
Seattle Genetics, Takeda report phase III AETHERA clinical trial data from ADCETRIS
Seattle Genetics, and Takeda Pharmaceutical Company reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001).
Drug Research > Drug Discovery & Development > News
ImmunoCellular gets EMA positive regulatory feedback on advancing ICT-107 to phase III program
ImmunoCellular Therapeutics announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM).
Drug Research > Drug Discovery & Development > News
91-105 of 3926 results